M6075535
TPX-0005 , 99% , 1802220-02-5
CAS NO.：1802220-02-5
Empirical Formula: C18H18FN5O2
Molecular Weight: 355.37
MDL number: MFCD31544350
| Pack Size | Price | Stock | Quantity |
| 5mg | RMB834.40 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Density | 1.46±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO:35.0(Max Conc. mg/mL);98.5(Max Conc. mM) Ethanol:10.0(Max Conc. mg/mL);28.1(Max Conc. mM) |
| form | A crystalline solid |
| pka | 10.79±0.60(Predicted) |
| color | White to off-white |
| InChI | InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1 |
| InChIKey | FIKPXCOQUIZNHB-WDEREUQCSA-N |
| SMILES | O1C2=CC=C(F)C=C2[C@@H](C)NC2C=CN3C(N=2)=C(C=N3)C(=O)NC[C@@H]1C |
Description and Uses
Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much smaller size (MW <370) than current ROS1 inhibitors. It was specifically designed to overcome resistance mutations. Preclinical studies have shown activity against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M, S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103].
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
